Compare RLX Technology Inc (RLX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs GeneDx Holdings Corp — how do they compare? RLX Technology Inc trades at $1.73 (market cap $2.10B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: RLX Technology Inc and GeneDx Holdings Corp are close in size by market cap, and RLX Technology Inc pays a 5.81% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 35 Days and GeneDx Holdings Corp for 19 Days on average.
| RLX | WGS | |
|---|---|---|
Market Cap | $2.10B | $2.02B |
Volume | 1,079,706 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $167.51 |
52-Week Low | $1.68 | $34.51 |
Typical Hold Time | 35 Days | 19 Days |
Enterprise Value | $832.26M | $2.05B |
Dividend Yield | 5.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.735, up 0.29% with bearish technical signals despite recent 52-week lows. The company shows solid fundamentals with $3.62B revenue, 21.87% net margin, and attractive valuation at P/E 15.46 and P/B 0.91. Recent earnings missed expectations but international expansion drives growth, with 70% revenue now from overseas markets. Cash flow trends improved significantly from -$99M in 2025 to $881M projected for 2026.
RLX presents a value opportunity with discounted valuation and strong international growth, though technical weakness and earnings misses warrant caution. The single analyst coverage maintains Hold rating, reflecting uncertainty amid expansion execution risks and regulatory challenges in the e-vapor industry.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
